Sage’s PPD drug to cost $15K; Ab­cam share­hold­ers vote 'yes' on Dana­her deal

Plus, news about Sen­ti Bio­sciences, Ce­lest Ther­a­peu­tics and Au­ra Bio­sciences:

Sage’s post­par­tum de­pres­sion drug to cost $15K for 14 days: The com­pa­ny an­nounced Tues­day that it set the whole­sale ac­qui­si­tion cost for Zurzu­vae at $15,900 for a 14-day course of treat­ment. The FDA this sum­mer ap­proved the ther­a­py as a treat­ment for women with post­par­tum de­pres­sion. Leerink an­a­lysts pre­vi­ous­ly pre­dict­ed that Sage would price Zurzu­vae be­tween $10,000 and $35,000.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA